At the crossroads from bench to bedside: luteolin is a promising pharmacological agent against myocardial ischemia reperfusion injury

The study by Bian et al. (1) found that luteolin (Lut) inhibited myocardial ischemia/reperfusion injury (IRI) by decreasing miR-208b-3p and increasing Ets1 expression levels in rats. Cokkinos (2) has written an editorial commentary for this study and considered it to be elegant. However, he also raised several interesting questions about the study. As the members of the investigate team, we would like to discuss these issues with counterparts.